Compound class:
Synthetic organic
Comment: The discovery of the TL-77, is described in [2] (and also as compound 9a in [1]). This compound is reported to have improved oral bioavailability compared to rigosertib, and represents a lead anti-mitotic, anti-cancer agent with potential for further development.
|
|
References |
1. Lu T, Goh AW, Yu M, Adams J, Lam F, Teo T, Li P, Noll B, Zhong L, Diab S et al.. (2014)
Discovery of (E)-3-((styrylsulfonyl)methyl)pyridine and (E)-2-((styrylsulfonyl)methyl)pyridine derivatives as anticancer agents: synthesis, structure-activity relationships, and biological activities. J Med Chem, 57 (6): 2275-91. [PMID:24471873] |
2. Lu T, Laughton CA, Wang S, Bradshaw TD. (2015)
In vitro antitumor mechanism of (E)-N-(2-methoxy-5-(((2,4,6-trimethoxystyryl)sulfonyl)methyl)pyridin-3-yl)methanesulfonamide. Mol Pharmacol, 87 (1): 18-30. [PMID:25316768] |